WO2022011021A1 - Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine - Google Patents

Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine Download PDF

Info

Publication number
WO2022011021A1
WO2022011021A1 PCT/US2021/040700 US2021040700W WO2022011021A1 WO 2022011021 A1 WO2022011021 A1 WO 2022011021A1 US 2021040700 W US2021040700 W US 2021040700W WO 2022011021 A1 WO2022011021 A1 WO 2022011021A1
Authority
WO
WIPO (PCT)
Prior art keywords
cov
ecd
peptide
tremll
vaccine
Prior art date
Application number
PCT/US2021/040700
Other languages
English (en)
French (fr)
Inventor
Yen-Ta Lu
Chia-Ming Chang
Ping-Yen Huang
Original Assignee
Ascendo Biotechnology, Inc.
LEE, Frank Wen-Chi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendo Biotechnology, Inc., LEE, Frank Wen-Chi filed Critical Ascendo Biotechnology, Inc.
Publication of WO2022011021A1 publication Critical patent/WO2022011021A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PCT/US2021/040700 2020-07-07 2021-07-07 Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine WO2022011021A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063048655P 2020-07-07 2020-07-07
US63/048,655 2020-07-07

Publications (1)

Publication Number Publication Date
WO2022011021A1 true WO2022011021A1 (en) 2022-01-13

Family

ID=79552016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/040700 WO2022011021A1 (en) 2020-07-07 2021-07-07 Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine

Country Status (2)

Country Link
TW (1) TW202208400A (zh)
WO (1) WO2022011021A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus
WO2024038155A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against viral infections disease(s)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
US20120164174A1 (en) * 2009-06-25 2012-06-28 Bioleaders Corporation Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles
US20170340725A1 (en) * 2015-10-22 2017-11-30 Modernatx, Inc. Combination piv3/hmpv rna vaccines
US20180141991A1 (en) * 2015-06-12 2018-05-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse
US20200061185A1 (en) * 2016-10-25 2020-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Prefusion coronavirus spike proteins and their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
US20120164174A1 (en) * 2009-06-25 2012-06-28 Bioleaders Corporation Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles
US20180141991A1 (en) * 2015-06-12 2018-05-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse
US20170340725A1 (en) * 2015-10-22 2017-11-30 Modernatx, Inc. Combination piv3/hmpv rna vaccines
US20200061185A1 (en) * 2016-10-25 2020-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Prefusion coronavirus spike proteins and their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus
WO2024038155A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against viral infections disease(s)

Also Published As

Publication number Publication date
TW202208400A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
EP3156068B1 (en) Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
JP2023513693A (ja) ＳＡＲＳ－ＣｏＶ－２ワクチン
JPH09501933A (ja) 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化
WO2022011021A1 (en) Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine
WO2021203017A2 (en) Biodegradable nanocomplex vaccines, methods for prevention of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection
KR20220010478A (ko) 기도 감염의 치료 또는 예방용 서브유닛 백신
US20230256082A1 (en) Vaccine against human-pathogenic coronaviruses
WO2021207281A2 (en) Vaccines, adjuvants, and methods of generating an immune response
JP2022525431A (ja) 抗原性多量体呼吸器合胞体ウイルスポリペプチド
WO2010031113A1 (en) Viral polypeptides and methods
KR20230022160A (ko) 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
WO2012040266A2 (en) Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
EP4144752A1 (en) Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus
US20110311569A1 (en) HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
Blanas et al. Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19
WO2022253193A1 (zh) 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
WO2023183136A1 (en) Composition comprising antigen and dna and use thereof
CA3157810A1 (en) Vaccines against coronaviruses
JP2024518565A (ja) 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤
JP2023182231A (ja) Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用
CA3100236A1 (en) Severe acute respiratory syndrome coronavirus dna vaccines
TW202142553A (zh) 用於預防嚴重急性呼吸道症候群冠狀病毒2(SARS-CoV-2)感染之生物可分解奈米複合物疫苗及方法
CN117279659A (zh) 人偏肺病毒疫苗

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838160

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21838160

Country of ref document: EP

Kind code of ref document: A1